Insulin sensitizers for the treatment of non-alcoholic fatty liver disease

Table 2 Summary of thiazolidinedione trials in adult patients with non-alcoholic fatty liver disease/non-alcoholic

Ref.	Study type	Subject number	Therapy	Compared with	Duration	NAFLD vs NASH	Liver enzymes	Histology
Caldwell et al[53]	Open label, single arm	10	Troglitazone	Baseline	< 6 mo	NASH	Improved	Mildly improved
Neuschwander-Tetri et al[54]	Open label, single arm	30	Rosiglitazone	Baseline	48 wk	NASH	Improved	Improved
Promrat et al[55]	Open label, single arm	18	Pioglitazone	Baseline	48 wk	NASH	Improved	Improved
Sanyal et al[56]	Open label, RCT	20	Pioglitazone + Vitamin E	Vitamin E	6 mo	NASH	Improved	Improved
Belfort et al[57]	Blinded, RCT	55	Pioglitazone	Placebo	6 mo	NASH	Improved	Improved
Idilman et al[58]	Open label, RCT	74	Rosiglitazone	Metformin/life style modification	48 wk	NASH	Improved	Improved
Ratziu et al[59]	Blinded, RCT	63	Rosiglitazone	Placebo	12 mo	NASH	Improved	Improved
Omer et al[60]	Open label, RCT	64	Rosiglitazone	Metformin	12 mo	NAFLD	Improved	Improved
Sanyal et al[61]	Blinded, RCT	274	Pioglitazone	Placebo and vitamin E	24 mo	NASH	Improved	Improved

NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; RCT: Randomized controlled trials.